VIP217 / Vincerx - LARVOL DELTA

Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform (GlobeNewswire) - “Vincera Pharma, Inc…announced the signing of an exclusive license agreement with Bayer AG for the development and commercialization of an early development oncology portfolio…Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152)…Additionally, Vincera will receive assets and license technology for a preclinical bioconjugation platform to address the limitations of small-molecule and antibody-drug conjugates in oncology. The preclinical assets include: VIP236...targeting advanced and metastatic cancer; as well as VIP943 (formerly BAY-943) and VIP924 (formerly BAY-924), two antibody-drug conjugates (ADC) targeting hematologic tumors; and VIP217…’with proof-of-concept clinical data in hand, we are poised to execute on a strategic clinical development plan with the potential for multiple accelerated approvals in the U.S. Expansion of the current Phase 1b study to include these patient populations is expected to begin in 2021.’”

Licensing / partnership • New P1 trial • Hematological Malignancies • Oncology